Paolo Tarantino: Interesting Results From a 1L Trial of CDK4/6 Inhibitors in Triple-Positive MBC at ASCO 2025
May 31, 2025, 11:04

Paolo Tarantino: Interesting Results From a 1L Trial of CDK4/6 Inhibitors in Triple-Positive MBC at ASCO 2025

Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:

Interesting results from a 1L trial of ET+ribo+ trastuzumab for HR+/HER2+ MBC (n=90). ORR 61%, mPFS 30 months. Confirming what we’re realizing more and more: patients with triple-positive metastatic disease NEED to receive a CDK4/6 inhibitor at part of their 1L treatment.

Paolo Tarantino

More posts featuring ASCO25.